BISAP评分联合血清sRAGE评估急性高脂血症性胰腺炎严重程度和短期预后的价值

doi:10.3969/j.issn.1673-8640.2023.07.007

摘要/Abstract

摘要：

目的探讨急性胰腺炎严重程度床旁指数（BISAP）评分联合血清可溶性晚期糖基化终产物受体（sRAGE）对急性高脂血症性胰腺炎（HLAP）严重程度和预后评估的价值。方法选取2017年3月—2022年8月安徽医科大学第二附属医院HLAP患者142例。对所有患者行急性生理与慢性健康评分Ⅱ（APACHE Ⅱ）、序贯器官衰竭估计（SOFA）评分和BISAP评分。收集所有患者的临床资料和实验室检测结果，并检测血清sRAGE水平。根据BISAP评分结果将患者分为重症HLAP（重症组，54例）和非重症HLAP（非重症组，88例）。根据患者入院30 d的生存状态分为死亡组（42例）和非死亡组（100例）。采用Logistic回归分析评估HLAP患者入院30 d死亡的危险因素。采用受试者工作特征（ROC）曲线评价各项指标鉴别诊断重症HLAP和判断HLAP患者入院30 d死亡的效能。结果与非重症组比较，重症组APACHE Ⅱ评分、SOFA评分和sRAGE水平均显著升高（P<0.05）。与非死亡组比较，死亡组C反应蛋白（CRP）、sRAGE水平和BISAP评分≥3分所占比例、APACHE Ⅱ评分、SOFA评分均显著升高（P<0.05）。多因素Logistic回归分析结果显示，APACHE Ⅱ评分升高和sRAGE水平升高均是重症HLAP的危险因素[比值比（OR）值分别为1.17和1.01，95%可信区间（CI）分别为1.03~1.34和1.00~1.01]。BISAP评分≥3分和血清sRAGE水平是HLAP患者入院30 d死亡的危险因素（OR值分别为1.99和1.01，95%CI分别为1.53~2.98和1.00~1.03）。sRAGE鉴别诊断重症HLAP的曲线下面积（AUC）为0.73。BISAP评分、sRAGE单项和联合检测判断HLAP患者入院30 d死亡的AUC分别为0.81、0.67、0.86。CRP、SOFA评分、APACHE Ⅱ评分和sRAGE联合检测鉴别诊断重症HLAP的AUC为0.77。CRP、SOFA评分、APACHE Ⅱ评分、sRAGE和BISAP评分联合检测判断HLAP患者入院30 d死亡的AUC为0.89。结论 sRAGE对HLAP患者病情严重程度的判断有一定意义。联合应用sRAGE和BISAP评分有助于提高对患者短期预后的评估效能。

关键词: 可溶性晚期糖基化终产物受体, 急性胰腺炎严重程度床旁指数评分, 高脂血症性胰腺炎

Abstract:

Objective To investigate the efficacy of bedside index for severity in acute pancreatitis（BISAP） score combined with serum soluble receptor for advanced glycation end product（sRAGE） for predicting the severity and prognosis in hyperlipidemic acute pancreatitis（HLAP）. Methods A total of 142 HLAP patients admitted to the Second Affiliated Hospital of Anhui Medical University from March 2017 to August 2022 were enrolled. The acute physiology and chronic health evaluation Ⅱ（APACHE Ⅱ），sequential organ failure assessment（SOFA） and BISAP were scored. The clinicopathologic data and clinical laboratory determination results were collected，and serum sRAGE levels were determined. The patients were classified into severe HLAP（severe group，54 cases） and non-severe HLAP（non-severe group，88 cases） according to BISAP score. According to the 30 d survival status after admission，the patients were classified into death group（42 cases） and survival group（100 cases）. Logistic regression analysis was used to evaluate the risk factors for 30 d admission death in HLAP patients. Receiver operating characteristic（ROC） curve was used to evaluate the differential diagnosis of severe HLAP and death at 30 d after admission. Results The levels of APACHEⅡ score，SOFA score and sRAGE were increased in severe group compared with non-severe group（P<0.05）. Compared with survival group，C-reactive protein（CRP），sRAGE，BISAP score≥3 points，APACHEⅡ score and SOFA score in death group were increased（P<0.05）. Multivariate Logistic regression analysis showed that increased APACHE Ⅱ score and increased sRAGE level were risk factors for severe HLAP [odds ratios（OR） were 1.17 and 1.01，95% confidence intervals（CI） were 1.03-1.34 and 1.00-1.03，respectively]. BISAP score ≥3 and serum sRAGE level were risk factors for death at 30 d after admission in HLAP patients（OR=1.99 and 1.01，95% CI 1.53-2.98 and 1.00-1.01，respectively）. The area under curve（AUC） of sRAGE for differential diagnosis of severe HLAP was 0.73. The AUC of BISAP score，sRAGE single and combined determinations for HLAP patients were 0.81，0.67 and 0.86，respectively. The AUC of CRP，SOFA score，APACHE Ⅱ score and sRAGE in the differential diagnosis of severe HLAP was 0.77. The AUC of combined determination of CRP，SOFA score，APACHEⅡ score，sRAGE and BISAP score for death in 30 d among HLAP patients after admission was 0.89. Conclusions The sRAGE plays a role in assessing HLAP severity. The combined determination of sRAGE and BISAP score can improve the assessment efficacy of short-term prognosis in HLAP.

Key words: Soluble receptor for advanced glycation end product, Bedside index for severity in acute pancreatitis score, Hyperlipidemic acute pancreatitis

中图分类号:

R446.62

汪海平, 李贺. BISAP评分联合血清sRAGE评估急性高脂血症性胰腺炎严重程度和短期预后的价值[J]. 检验医学, 2023, 38(7): 653-658.

WANG Haiping, LI He. BISAP score combined with serum sRAGE for predicting hyperlipidemic acute pancreatitis severity and short-term prognosis[J]. Laboratory Medicine, 2023, 38(7): 653-658.

图/表 9

参考文献 23

[1]	HUANG Y X, JIA L, JIANG S M, et al. Incidence and clinical features of hyperlipidemic acute pancreatitis from Guangdong,China:a retrospective multicenter study[J]. Pancreas, 2014, 43(4):548-552. DOI URL
[2]	GUBENSEK J, BUTUROVIC-PONIKVAR J, ROMOZI K, et al. Factors affecting outcome in acute hypertriglyceridemic pancreatitis treated with plasma exchange:an observational cohort study[J]. PLoS One, 2014, 9(7):e102748. DOI URL
[3]	WANG Y H, XU Z H, ZHOU Y H, et al. The clinical characteristic of biliary-hyperlipidemic etiologically complex type of acute pancreatitis:a retrospective study from a tertiary center in China[J]. Eur Rev Med Pharmacol Sci, 2021, 25(3):1462-1471.
[4]	HAGJER S, KUMAR N. Evaluation of the BISAP scoring system in prognostication of acute pancreatitis-a prospective observational study[J]. Int J Surg, 2018, 54(Pt A):76-81. DOI URL
[5]	YANG Y X, LI L. Evaluating the ability of the bedside index for severity of acute pancreatitis score to predict severe acute pancreatitis:a meta-analysis[J]. Med Princ Pract, 2016, 25(2):137-142. DOI URL
[6]	RAO N L, KOTIAN G B, SHETTY J K, et al. Receptor for advanced glycation end product,organ crosstalk,and pathomechanism targets for comprehensive molecular therapeutics in diabetic ischemic stroke[J]. Biomolecules, 2022, 12(11):1712. DOI URL
[7]	SHEN X, LI W Q. High-mobility group box 1 protein and its role in severe acute pancreatitis[J]. World J Gastroenterol, 2015, 21(5):1424-1435. DOI URL
[8]	MAO E Q, TANG Y Q, ZHANG S D. Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis[J]. World J Gastroenterol, 2003, 9(11):2622-2626. DOI URL
[9]	中华医学会消化病学分会胰腺疾病学组, 中华胰腺病杂志编辑委员会, 中华消化杂志编辑委员会. 中国急性胰腺炎诊治指南(2013年,上海)[J]. 中华消化杂志, 2013, 33(4):217-222.
[10]	HARSHIT KUMAR A, SINGH GRIWAN M. A comparison of APACHE Ⅱ,BISAP,Ranson's score and modified CTSI in predicting the severity of acute pancreatitis based on the 2012 revised Atlanta Classification[J]. Gastroenterol Rep(Oxf), 2018, 6(2):127-131.
[11]	TEE Y S, FANG H Y, KUO I M, et al. Serial evaluation of the SOFA score is reliable for predicting mortality in acute severe pancreatitis[J]. Medicine(Baltimore), 2018, 97(7):e9654.
[12]	PARK J Y, JEON T J, HA T H, et al. Bedside index for severity in acute pancreatitis:comparison with other scoring systems in predicting severity and organ failure[J]. Hepatobiliary Pancreat Dis Int, 2013, 12(6):645-650. DOI URL
[13]	POPA C C, BADIU D C, RUSU O C, et al. Mortality prognostic factors in acute pancreatitis[J]. J Med Life, 2016, 9(4):413-418. PMID
[14]	YANG L, LIU J, XING Y, et al. Comparison of BISAP,Ranson,MCTSI,and APACHE Ⅱ in predicting severity and prognoses of hyperlipidemic acute pancreatitis in Chinese patients[J]. Gastroenterol Res Pract, 2016, 2016:1834256.
[15]	ARIF A, JALEEL F, RASHID K. Accuracy of BISAP score in prediction of severe acute pancreatitis[J]. Pak J Med Sci, 2019, 35(4):1008-1012. DOI PMID
[16]	LECLERC E, VETTER S W. The role of S100 proteins and their receptor RAGE in pancreatic cancer[J]. Biochim Biophys Acta, 2015, 1852(12):2706-2711. DOI PMID
[17]	LINDSTRÖM O, TUKIAINEN E, KYLÄNPÄÄ L, et al. Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis[J]. Pancreas, 2009, 38(8):e215-e220. DOI URL
[18]	SHAN L, BAI S, ZHAO M. Early diagnosis of serum sICAM-1 and sRAGE in severe acute pancreatitis,and efficacy and prognosis prediction of glutamine combined with ulinastatin[J]. Exp Ther Med, 2021, 21(4):324. DOI URL
[19]	高莉莎, 王瑞, 任宏飞, 等. 血清可溶性晚期糖基化终产物受体、降钙素原水平预测高脂血症性急性胰腺炎严重程度及预后的临床价值[J]. 实用医院临床杂志, 2021, 18(2):70-73.
[20]	KOCSIS A K, SZABOLCS A, HOFNER P, et al. Plasma concentrations of high-mobility group box protein 1,soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis[J]. Pancreatology, 2009, 9(4):383-391. DOI URL
[21]	ZHAO B, CHEN Y, SUN W W, et al. Effect of S100A12 and soluble receptor for advanced glycation end products on the occurrence of severe acute pancreatitis[J]. J Dig Dis, 2016, 17(7):475-482. DOI URL
[22]	HUDSON B I, GARDENER H, LIU-MARES W, et al. Serum soluble RAGE levels and carotid atherosclerosis:the Northern Manhattan Study(NOMAS)[J]. Atherosclerosis, 2015, 240(1):17-20. DOI URL
[23]	BRODSKA H, MALICKOVA K, VALENTA J, et al. Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis[J]. Scand J Clin Lab Invest, 2013, 73(8):650-660. DOI PMID

组别	例数	年龄/岁	性别		BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
重症组	54	43.34±9.17	40（74.07）	14（25.93）	23.75±2.32	14（25.93）	11（20.37）	15（27.78）
非重症组	88	40.68±9.54	69（78.41）	19（21.59）	23.81±2.71	17（19.32）	18（20.45）	30（34.09）
统计值		1.640	0.350		-0.120	0.860	0.010	0.620
P值		0.100	0.550		0.910	0.350	0.990	0.430

组别	例数	年龄/岁	性别		BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
重症组	54	43.34±9.17	40（74.07）	14（25.93）	23.75±2.32	14（25.93）	11（20.37）	15（27.78）
非重症组	88	40.68±9.54	69（78.41）	19（21.59）	23.81±2.71	17（19.32）	18（20.45）	30（34.09）
统计值		1.640	0.350		-0.120	0.860	0.010	0.620
P值		0.100	0.550		0.910	0.350	0.990	0.430

组别	例数	年龄/岁	性别		BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
死亡组	42	40.43±9.68	32（76.19）	10（23.81）	24.01±2.45	9（21.43）	10（23.81）	14（33.33）
非死亡组	100	42.44±9.44	77（77.00）	23（23.00）	23.69±2.62	22（22.00）	19（19.00）	31（31.00）
统计值		-1.020	0.010		0.700	0.006	0.420	0.070
P值		0.310	0.920		0.490	0.940	0.520	0.790

组别	例数	年龄/岁	性别		BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	BMI/ （kg/m²）	高血压/ [例（%）]	糖尿病/ [例（%）]	动脉氧分压<7.98 kPa/[例（%）]
死亡组	42	40.43±9.68	32（76.19）	10（23.81）	24.01±2.45	9（21.43）	10（23.81）	14（33.33）
非死亡组	100	42.44±9.44	77（77.00）	23（23.00）	23.69±2.62	22（22.00）	19（19.00）	31（31.00）
统计值		-1.020	0.010		0.700	0.006	0.420	0.070
P值		0.310	0.920		0.490	0.940	0.520	0.790

项目	β值	标准误	Wald值	OR值（95%CI）	P值
CRP	0.007	0.007	1.12	1.01（0.99~1.02）	0.290
APCHE Ⅱ评分	0.160	0.070	3.38	1.17（1.03~1.34）	0.020
SOFA评分	0.080	0.060	1.76	1.08（0.96~1.22）	0.190
sRAGE	0.005	0.002	8.20	1.01（1.00~1.01）	0.004